Changes in Hepcidin and Reticulocyte Hemoglobin Equivalent Levels in Response to Continuous Erythropoietin Receptor Activator Administration in Hemodialysis Patients: A Randomized Study

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 5, 2014, Pages 421-426

  Kakimoto Shino, Midori ^a   Toya, Yoshiyuki ^a   Kuji, Tadashi ^a,b   Fujikawa, Tetsuya ^a,c   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yokodai Eye Clinic   (Japan)

^c YOKOHAMA NATIONAL UNIVERSITY   (Japan)

Author keywords

Anemia; Epoetin beta pegol; Erythropoiesis stimulating agents; Hemodialysis; Hepcidin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

AGED; ARTICLE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SUBSTITUTION; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; IRON BINDING CAPACITY; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETICULOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TIME;

AGED; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETICULOCYTES; TIME FACTORS; TRANSFERRIN;

EID: 84909980130     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12161     Document Type: Article

References (24)

1. Pisoni RL, Bragg-Gresham JL, Young EW etal. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111.
2. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002;17(Suppl):53-59.
3. López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008;111:S75-81.
4. Fujikawa T, Ikeda Y, Fukuhara S etal. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan dialysis outcomes and practice patterns study. Nephron Clin Pract 2012;122:24-32.
5. Hörl WH, Jacobs C, Macdougall IC etal. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 2000;15(Suppl 4):43-50.
6. Coyne DW, Kapoian T, Suki W etal. DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-984.
7. Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, Hasuike Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012;16:819-826.
8. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44:866-876.
9. Feldman HI, Santanna J, Guo W etal. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002;13:734-744.
10. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
11. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica 2008;93:90-97.
12. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
13. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-440.
14. Macdougall IC, Robson R, Opatrna S etal. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211-1215.
15. Miwa N, Akiba T, Kimata N etal. Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. Int J Lab Hematol. 2010;32:248-255.
16. Jonckheere S, Dierick J, Vanhouteghem H, Devleeschouwer M, Stove V. Erythrocyte indices in the assessment of iron status in dialysis-dependent patients with end-stage renal disease on continuous erythropoietin receptor activator versus epoetin beta therapy. Acta Haematol 2010;124:27-33.
17. Garzia M, Di Mario A, Ferraro E etal. Reticulocyte hemoglobin equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy. Lab Hematol 2007;13:6-11.
18. Schaefer RM, Bahner U. Iron metabolism in rhEPO-treated hemodialysis patients. Clin Nephrol 2000;53(1 Suppl):S65-68.
19. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007;21:4033-4038.
20. Canals C, Remacha AF, Sardá MP, Piazuelo JM, Royo MT, Romero MA. Clinical utility of the new Sysmex XE 2100 parameter-reticulocyte hemoglobin equivalent-in the diagnosis of anemia. Haematologica 2005;90:1133-1134.
21. Tsubakihara Y, Nishi S, Akiba T etal. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-275.
22. Ashby DR, Gale DP, Busbridge M etal. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-981.
23. van der Putten K, Jie KE, van den Broek D etal. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail. 2010;12:943-950.
24. Fliser D, Kleophas W, Dellanna F etal. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010;26:1083-1089.